title: Vaginal hysterectomy as primary treatment of endometrial cancer in medically compromised women.
abstract: OBJECTIVE
  To study the survival, rates and patterns of recurrence, and perioperative morbidity in medically compromised women with endometrial cancer treated by primary vaginal hysterectomy.
  
  
  METHODS
  Fifty-one patients with endometrial cancer treated initially by vaginal hysterectomy between 1977 and 1999 were identified at the University of California, Irvine Medical Center and affiliated hospitals. Data were retrieved from hospital and office records. Statistical analysis, including Kaplan-Meier methods, was performed and the disease-specific survival rates were estimated. This study has 80% power to demonstrate a greater than 20% improvement in 5-year survival over historical controls.
  
  
  RESULTS
  Fifty-one women with uterine carcinoma clinically confined to the uterus underwent primary vaginal hysterectomy with (n = 26) or without (n = 25) salpingo-oophorectomy. Eighty-four percent were obese with a body mass index greater than 27. Additional risk factors for surgical complications included hypertension (57%), diabetes mellitus (27%), and cardiovascular disease (18%). One-third of patients had three or more risk factors. Surgical morbidity included one episode of acute hemorrhage necessitating transfusion and abdominal exploration. Blood transfusions were given to four additional patients. There were no perioperative deaths. Five women recurred and expired at a median of 13 months (range 3--53 months) after surgery. The 3- and 5-year disease-specific survival rates were 91.4% and 88.0%, respectively.
  
  
  CONCLUSIONS
  Vaginal hysterectomy for the initial treatment of early-stage endometrial cancer is associated with a high rate of cure and minimal morbidity. Thus, it may be considered a reasonable alternative to the abdominal approach in medically compromised women.
authors.affiliation: Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine--Medical Center, Orange, California 92868, USA.
authors.forename: J K
authors.initials: JK
authors.lastname: Chan
authors.forename: Y G
authors.initials: YG
authors.lastname: Lin
authors.forename: B J
authors.initials: BJ
authors.lastname: Monk
authors.forename: K
authors.initials: K
authors.lastname: Tewari
authors.forename: J D
authors.initials: JD
authors.lastname: Bloss
authors.forename: M L
authors.initials: ML
authors.lastname: Berman
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D002318:Cardiovascular Diseases / Q000453:epidemiology; D015897:Comorbidity; D016001:Confidence Intervals; D003920:Diabetes Mellitus / Q000453:epidemiology; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007045:Hysterectomy, Vaginal / Q000379:methods* / Q000401:mortality; D008875:Middle Aged; D009367:Neoplasm Staging; D009765:Obesity / Q000453:epidemiology; D011336:Probability; D012042:Registries; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome